Discontinued — last reported Q3 '23
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)
Biogen Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) increased by 12.1% to $650.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 2.3%, from $665.00M to $650.00M. Over 3 years (FY 2020 to FY 2023), Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) shows an upward trend with a 28.7% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
Higher values indicate a larger near-term drag on reported earnings due to previous acquisition activity.
Detailed definition
This represents the projected non-cash expense related to the amortization of finite-lived intangible assets for the upc...
Peer comparison
Companies with high M&A activity in the medical device space typically report significant annual amortization expenses.
finite_lived_intangible_assets_amortization_year_1Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $220.00M | $195.00M | $195.00M | $180.00M | $180.00M | $175.00M | $175.00M | $170.00M | $170.00M | $435.00M | $480.00M | $710.00M | $710.00M | $615.00M | $665.00M | $665.00M | $580.00M | $650.00M |
| QoQ Change | — | -11.4% | +0.0% | -7.7% | +0.0% | -2.8% | +0.0% | -2.9% | +0.0% | +155.9% | +10.3% | +47.9% | +0.0% | -13.4% | +8.1% | +0.0% | -12.8% | +12.1% |
| YoY Change | — | — | — | — | -18.2% | -10.3% | -10.3% | -5.6% | -5.6% | +148.6% | +174.3% | +317.6% | +317.6% | +41.4% | -6.3% | -6.3% | -5.7% | -2.3% |
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) at Other Companies
Frequently Asked Questions
- What is Biogen's finite-lived intangible assets - expected amortization expense (year one)?
- Biogen (BIIB) reported finite-lived intangible assets - expected amortization expense (year one) of $650.00M in Q1 2026.
- How has Biogen's finite-lived intangible assets - expected amortization expense (year one) changed year-over-year?
- Biogen's finite-lived intangible assets - expected amortization expense (year one) decreased by 2.3% year-over-year, from $665.00M to $650.00M.
- What is the long-term trend for Biogen's finite-lived intangible assets - expected amortization expense (year one)?
- Over 3 years (2020 to 2023), Biogen's finite-lived intangible assets - expected amortization expense (year one) has grown at a 28.7% compound annual growth rate (CAGR), from $225.00M to $480.00M.
- What does finite-lived intangible assets - expected amortization expense (year one) mean?
- The expected non-cash expense for amortizing intangible assets over the next twelve months.